Precigen (NASDAQ:PGEN) and Vitality Biopharma (OTCMKTS:VBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, earnings, dividends, risk and valuation.
Volatility & Risk
Precigen has a beta of 2.09, indicating that its stock price is 109% more volatile than the S&P 500. Comparatively, Vitality Biopharma has a beta of 2.06, indicating that its stock price is 106% more volatile than the S&P 500.
This table compares Precigen and Vitality Biopharma’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Precigen and Vitality Biopharma’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Precigen||$90.72 million||6.41||-$322.32 million||($0.88)||-3.90|
|Vitality Biopharma||$260,000.00||7.78||-$13.12 million||N/A||N/A|
Vitality Biopharma has lower revenue, but higher earnings than Precigen.
This is a breakdown of recent ratings for Precigen and Vitality Biopharma, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional and Insider Ownership
74.1% of Precigen shares are held by institutional investors. Comparatively, 0.2% of Vitality Biopharma shares are held by institutional investors. 44.0% of Precigen shares are held by company insiders. Comparatively, 8.7% of Vitality Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Precigen beats Vitality Biopharma on 6 of the 10 factors compared between the two stocks.
Precigen Company Profile
Precigen, Inc. engages in the engineering and industrialization of biology in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. It provides reproductive technologies and other genetic processes to cattle breeders and producers; biological insect control solutions; technologies for non-browning apple without the use of artificial additives; genetically engineered swine for medical and genetic research; commercial aquaculture products; and preservation and cloning technologies. The company also offers UltraVector platform that enables design and assembly of gene programs that facilitate control over the quality, function, and performance of living cells; and RheoSwitch inducible gene switch that provides quantitative dose-proportionate regulation of the amount and timing of target protein expression. In addition, it provides AttSite Recombinases, which allows stable, targeted gene integration and expression; LEAP automated platform to identify and purify cells of interest, such as antibody expressing cells and stem cells; ActoBiotics platform for targeted in situ expression of proteins and peptides from engineered microbes; and AdenoVerse technology platform for tissue specificity and target selection. The company serves the health, food, energy, and environment markets. Precigen, Inc. has collaboration and license agreements with ZIOPHARM Oncology, Inc.; Ares Trading S.A.; Oragenics, Inc.; Intrexon T1D Partners, LLC; Intrexon Energy Partners, LLC; Intrexon Energy Partners II, LLC; Genopaver, LLC; Fibrocell Science, Inc.; Persea Bio, LLC; OvaXon, LLC; S & I Ophthalmic, LLC; Harvest start-up entities; and Surterra Wellness. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in January 2020. Precigen, Inc. was founded in 1998 and is based in Germantown, Maryland.
Vitality Biopharma Company Profile
Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company's products in pipeline include VBX-100, an oral cannabinoid formulation for inflammatory bowel disease, C.difficile-associated diarrhea and colitis, and narcotic bowel syndrome; and VBX-210, a cannabinoid formulation, which is in preclinical studies for the treatment of gastrointestinal conditions. It develops additional cannabinoid product formulations for refractory pain and autism spectrum disorder. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. The company was founded in 2007 and is based in Los Angeles, California.
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.